Kausik Ray: Efficacy and Safety of Obicetrapib in Patients With HeFH on Maximally Tolerated Statins
Kausik Ray, Professor of Public Health at Imperial College London, Past President of European Atherosclerosis Society, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our key publication on the efficacy and safety of obicetrapib in patients with HeFH on maximally tolerated statins published in Nature Medicine. Well done, Stephen Nicholls.
Obicetrapib reduced LDL-C by ~ 36%, resulting in more patients achieving risk-based LDL-C goals and reduced Lp (a) meaningfully.
The ultimate test of this novel approach, CETPi, will come from PREVAIL.
Why it matters….. As we have shown (Hu et al., Circulation) HeFH occurs in 1:311 people globally. Our FHSC (Lancet 2021) showed globally the average age of diagnosis is 44 years, with less than 2% adults identified before the age of 18. This means that at detection, because of missed years of cholesterol exposure, 17% already have cardiovascular disease. Hence, we need to claw those years back with combination therapies. Only 2% of patients were at goal in the FHSC 2021 paper globally; we need effective, affordable treatments.
With obicetrapib expected in 2026 in Europe, we will have another tool in our arsenal to manage patients with HeFH.”
Title: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Authors: Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie L. Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael Szarek, Violeta Balinskaite, Michael H. Davidson
Read the Full Article on Nature Medicine
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS